Introduction
Important advances in neuraxial anesthetic practice have improved the quality of pain relief during labor 1 and enhanced post-cesarean analgesia, 2, 3 and reduced maternal morbidity and mortality (because of lower rates of general anesthesia for cesarean delivery). 4, 5 As a result, neuraxial anesthetic techniques, which include epidural, spinal, or combined spinal-epidural, have become established techniques for providing analgesia in labor and anesthesia for cesarean delivery. 6 Adverse neurologic outcomes associated with neuraxial anesthesia are fortunately rare; however, there is substantial concern regarding the implications of performing neuraxial techniques in patients receiving anticoagulation. The most feared complication is symptomatic spinal hematoma, which can be associated with devastating neurologic outcomes (such as lowerlimb paralysis). Early diagnosis and the patient's pre-operative neurological status are important factors that determine neurological outcome after surgical decompression to treat spinal hematoma. 7, 8 Anticoagulant therapy is an important etiological factor for spinal hematoma identified from case reports of patients receiving neuraxial anesthesia. 9 Spontaneous spinal hematoma formation can also occur in patients who do not undergo spinal instrumentation, and this has been recently reported in the obstetric literature in a patient receiving therapeutic anticoagulation with low-molecular weight heparin (LMWH). 10 The anesthetic management of pregnant patients receiving anticoagulation can be particularly challenging because of additional risks of spinal hematoma associated with spinal or epidural anesthesia. The unpredictable timing of labor and delivery may lead to uncertainty about using a neuraxial technique among anesthesiologists dealing with patients on anticoagulant or antithrombotic drugs. In addition, new anticoagulants are being introduced into clinical practice (for example fondaparinux, argatroban), 11 and there is limited information related to their safety in patients receiving neuraxial anesthesia. As a result, many anesthesia care providers may 'err on the side of caution' and choose not to offer a neuraxial technique to pregnant patients receiving anticoagulation. The implications of this empirical method of decision making are that anesthetic options for providing effective pain relief during labor and anesthesia for cesarean delivery become more limited. Furthermore, neuraxial anesthetic techniques are recommended for optimizing the anesthetic management for high-risk pregnant patients during the peripartum and postpartum periods. For example, airway management in morbidly obese patients undergoing general anesthesia for cesarean delivery can often pose major problems, and epidural catheter-based techniques for providing anesthesia are recommended for these patients. 12 Balancing the risks versus benefits of neuraxial anesthesia in pregnant patients receiving anticoagulation during the peripartum period requires careful consideration.
Current guidelines for the use of anticoagulation in pregnant patients from the Pregnancy and Thrombosis Working Group 13 and American College of Chest Physicians 14 include limited discussion of the implications of anticoagulation and the use of neuraxial anesthesia during the peripartum period. Guidelines for the safe timing and administration of central neuraxial blockade in patients receiving anticoagulant and antithrombotic agents have been produced by the American Society of Regional Anesthesia 15 and several European anesthetic societies. [16] [17] [18] [19] [20] [21] This review will acquaint obstetric care providers with summary information on the timing and provision of neuraxial anesthesia for patients receiving anticoagulant and antithrombotic agents. In addition, suggested algorithms for the peripartum management of patients on prophylactic and therapeutic unfractionated heparin (UFH) and LMWH will be outlined. The physiologic changes associated with pregnancy can lead to changes in the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of anticoagulant drugs, and relevant information is also described.
Spinal Hematoma: what is the risk of neuraxial anesthesia in pregnant patients receiving anticoagulation? Acquired or inherited conditions (associated with coagulation or bleeding diathesis) and anticoagulant drugs are important etiological factors for the development of spinal hematoma. 9, 22 Neuraxial anesthesia, which involves instrumentation of the epidural or subarachnoid space, can further increase the risk of spinal hematoma formation in anticoagulated patients. Spinal cord injury is thought to occur by direct compression from the overlying hematoma in the epidural space, or possibly by secondary ischemic injury of the spinal cord because of compression on spinal cord vessels. The early diagnosis of spinal hematoma is important in improving neurological outcomes, as the risk of permanent neurologic deficit (ranging from mild sensory deficit to paraplegia) is increased if hematoma evacuation is delayed >12 h after the onset of neurologic symptoms. 8, 9 Before the introduction of LMWHs, many anesthesiologists considered that the risk of spinal hematoma after neuraxial anesthesia was theoretical. 23 However, the introduction of LMWH in the United States in 1993 for surgical thromboprophylaxis was associated with an increase in the number of reported cases of spinal hematoma in patients receiving neuraxial anesthesia (>50 cases reported over a 5-year period). 24 The Food and Drug Administration in the United States intervened by issuing a health advisory in 1997 for LMWHs, 23, 25 and manufacturers of LWMHs and heparinoids were requested to produce 'boxed warnings' about the risk of spinal hematoma after neuraxial anesthesia on their products.
The results of several, large retrospective reviews suggest that the risk of spinal hematoma after neuraxial blockade in obstetric patients seems to be very low. Moen et al. 26 performed a retrospective review of adverse neurologic outcomes after neuraxial anesthesia in Sweden from 1990 to 1999. Two cases of spinal hematoma were reported after spinal anesthesia and epidural catheter removal, both in patients with HELLP syndrome. The reported rates of spinal hematoma after obstetric epidural and spinal blocks for cesarean delivery were 1:200 000 and 1:50 000, respectively. Data from other studies of complications after epidural blocks in obstetric patients (meta-analysis and national audit) indicate that the incidence of spinal hematoma is between 0 and 0.5:100 000. 27, 28 A review of obstetric anesthesia claims for injuries between 1990 and 2003 included four cases of epidural hematoma related to neuraxial anesthesia (out of a total of 426 claims). 29 Unfortunately, no supplementary background information was provided for each case. 29 An earlier systematic review of safety and efficacy of LMWH use in pregnancy included a subanalysis of 440 patients who received neuraxial anesthesia. In this study, no cases of spinal hematoma were reported; however, specific details of the timing and mode of neuraxial anesthesia were not included. 30 Although anticoagulant drugs can increase the risk of spinal hematoma after neuraxial anesthesia, the true incidence of spinal hematoma in obstetric patients receiving anticoagulant or antithrombotic drugs remains unknown.
Antenatal multi-disciplinary assessment for anticoagulated pregnant patients An antenatal anesthetic assessment and consultation is recommended for anticoagulated patients before the onset of labor or delivery. At our institution, all anticoagulated patients are referred by our obstetricians for an anesthesia consultation in advance of their estimated date of delivery. This consultation allows us to fully inform patients and their obstetricians about the indications and timing of neuraxial anesthesia for labor and delivery, and to discuss alternative anesthetic options if anticoagulant effects persist during the peripartum and early postpartum period.
The indications for anticoagulant therapy in the antenatal period include the prophylaxis and treatment of VTE in pregnancy, the prevention of systemic embolism in patients with mechanical heart valves, and the prevention of adverse pregnancy outcomes (for example early recurrent pregnancy loss, placental abruption) in patients with inherited or acquired thrombophilias. There is limited information available to guide physicians in managing anticoagulation during the peripartum period. The American College of Chest Physicians guidelines recommend discontinuing UFH or LMWH 24 h to 36 h before planned induction of labor or cesarean delivery for patients diagnosed with a venous thromboembolism during a current pregnancy.
14 Intravenous UFH therapy during labor is recommended for patients at 'very high risk' (for example proximal deep venous thrombosis or pulmonary embolism within 4 weeks of delivery) for recurrent venous thromboembolism.
14 No specific guidance is given for patients during the peripartum period requiring anticoagulation for other medical or obstetric indications. Owing to the lack of data, different approaches for managing anticoagulation have been described for laboring patients: to discontinue LWMH before or during labor, 31, 32 switch to subcutaneous (s.c.) heparin before delivery, 33 or use tailored intravenous heparin regimens in labor. 34 A survey of American College of Obstetricians and Gynecologists fellows investigating physician practice for managing pregnant patients with thrombophilia confirmed that similar variations in decision making exist for managing anticoagulation around the time of delivery. 35 As obstetric preferences for managing anticoagulated patients during the peripartum period may vary, it is important that there is close communication between obstetricians and anesthesiologists. We recommend that multi-disciplinary agreement is obtained on the planned timing and duration for an appropriate window period 'off anticoagulation' and for spinal/ epidural anesthesia during the peripartum period.
Guidelines for performing neuraxial anesthesia in anticoagulated patients
Guidelines and recommendations for neuraxial anesthesia from the American Society of Regional Anesthesia 15 and the European Society of Regional Anaesthesia 17 for patients receiving anticoagulation and antithrombotic drugs have been published. For the purposes of this review, we have outlined relevant information from these guidelines for the following drugs: UFH, LMWH, fondaparinux, aspirin, thienopyridines (clopidogrel, ticlopidine), and warfarin (Table 1) . These anesthesia society guidelines are limited by a lack of robust data assessing specific risk, and are based on consensus and expert opinion as well as information about PK and PD. There is understandable concern regarding the medico-legal implications of such guidelines on clinical practice, as well as uncertainty about whether these guidelines can be described as 'standard of care'. 36, 37 Nonetheless, it is likely that anesthesia care providers will adhere to these national guidelines on neuraxial anesthetic practice for patients receiving prophylactic or therapeutic anticoagulant drugs.
There is limited data of the pharmacological effect of these drugs in pregnant patients; therefore, descriptions of relevant PK-PD data from non-pregnant patients have been included. Summary information of the PK data for UFH, LMWH, fondaparinux, aspirin, thienopyridines (clopidogrel, ticlopidine), and warfarin is shown in Table 2 . As many of these drugs are irreversible or slowly reversible, the PK of specific drugs may not necessarily predict the PD profile.
Unfractionated heparin UFH is a highly sulfated glycosaminoglycan comprising a heterogeneous mixture of polysaccharide chains of varying lengths (3000 to 30 000D). UFH binds to antithrombin III, which subsequently interacts with thrombin (factor IIa), factor Xa, XIIa, XIa, IXa, and kallikrein. Current recommendations for the minimum time periods for heparin administration before and after neuraxial anesthesia are outlined in Table 1 . Guidelines from most anesthetic societies emphasize the need for the patient to have normal activated partial thromboplastin time (APTT) and/or activated clotting values before neuraxial anesthesia. In our experience, obstetric care providers are likely to encounter pregnant patients receiving s.c. UFH for thromboprophlyaxis. However, highrisk patients (for systemic or pulmonary emboli) may require intravenous heparin during the peripartum period. 38 Normal heparin clearance is associated with a rapid distribution phase followed by a zero-order elimination phase. A first-order process is assumed for heparin doses within the usual therapeutic range in the non-pregnant state. 39 However, pregnant patients will often be on higher dosing schedules because of pregnancy-induced heparin resistance. Lower peak plasma concentrations, lower peak changes in APTT, more attenuated APTT responses, and shorter onset times to peak plasma concentrations have been reported in third trimester pregnant patients receiving s.c. heparin compared with non-pregnant controls. 40, 41 These differences probably relate to a physiological increase in glomerular filtration rate, and an increase in non-specific protein binding and plasma volume with advancing gestation. To maintain therapeutic efficacy, UFH dosing/frequency may need to be increased because of the relative increase in heparin resistance with advancing pregnancy.
Low-molecular weight heparins
LMWHs are commonly used for prophylaxis and treatment of venous thromboembolism in the antenatal and postpartum periods.
A lower incidence of heparin-induced thrombocytopenia and osteoporosis and less frequent injections are potential advantages of LMWHs compared with UFH. 42 LMWHs are depolymerized porcine muscoal heparin preparations, and the molecular weight of individual LMWHs can vary between 4 and 8 kDa. The mechanism of action of LMWHs occurs by binding with antithrombin III, which augments the inhibitory effect of antithrombin III on thrombin, activated factor Xa, FIXa, FIIa, and kallikrein by a factor of X1000. 43 In addition, LMWHs also inhibit FVIIa/tissue factor (TF) complex formation, 44 induce the release of TF pathway inhibitor (TFPI) and augment the inhibitory effect of TFPI on FVIIa/TF complex formation. 45 The bioavailability of LMWHs is >90%, and t ½ values are generally twice as long as for UFH. Current recommendations for the minimum time periods for LMWH administration before and after neuraxial anesthesia are outlined in Table 1 .
There are marked differences in PK-PD properties between individual LMWH drugs, which are related to variability in the physicochemical structure of drugs in this class. In addition, anti-Xa activity assays, which are often used to estimate PD of LMWHs or monitor treatment, may vary because of individual differences in assay technique. There is also no standardization of assay techniques used to assess anti-Xa-and anti-IIa-specific activity; therefore, differences in anticoagulant effects between different LWMH preparations should be reviewed cautiously. 46 Earlier studies have investigated the PK-PD of LMWHs in pregnant patients to assess the efficacy of thromboprophlyaxis in the antenatal and postpartum periods. Many of these studies used PK-PD data as a means of assessing thromboprophylactic efficacy in 'at-risk' pregnant patients for venous thromboembolism.
An earlier study assessing thromboprophylaxis with s.c. tinzaparin (50, 75, or 100 IU kg -1 ; once a day) reported peak Neuraxial anesthesia with anticoagulant drugs AJ Butwick and B Carvalho anti-Xa levels at 4 h post-injection. 47 Patients receiving tinzaparin 50 IU kg -1 had significantly lower peak 4 h anti-Xa levels and reduced 24-h therapeutic activity (compared with 75 and 100 IU kg -1 ) between 28 and 36 weeks gestation. Peak anti-Xa activity at 4 h also occurs with s.c. dalteparin (5000 units; once a day) at 12, 24, and 36 weeks gestation. 48 Blomback et al. 49 studied the PK of s.c. dalteparin (2500 or 5000 units; once a day) in pregnant women at 32 to 35 weeks gestation and compared the results with historical controls. The maximal concentration (C max ), lag-time (T max ), and 24 h area under the curve values in the study group were 0.2 aXa IU ml -1 , 3 h, and 1.9 aXa IU h -1 ml -1 , respectively, which were all lower than observed in the control group.
Several studies have assessed the PK-PD of s.c. enoxaparin in pregnant and postpartum patients. Casele et al. investigated the PK of s.c. enoxaparin (40 mg daily) at three different time points (12 to 15 weeks gestation; 30 to 33 weeks gestation; 6 to 8 weeks postpartum). 50 Time to peak concentration was between 185 and 229 min in pregnant patients, which seems to be consistent with non-pregnant patients. Lebaudy et al. 51 performed a large population-based study assessing the PK of enoxaparin in pregnancy. In this study, the volume of distribution of enoxaparin was higher in the first trimester compared with the third trimester and the early postpartum period (>4 days postpartum), respectively, which is probably related to the increase in plasma volume in early pregnancy. Furthermore, the volume of distribution returns to normal 4 days after delivery. 51 Clearance of enoxaparin is higher in first trimester compared with the nonpregnant state, which is likely to be related to the pregnancyassociated increase in glomerular filtration rate that occurs in the first 16 weeks of gestation. The authors suggest that the reduction in peak anti-Xa activity will be approximately 20 and p10% between the first trimester and the 9th month in pregnant patients receiving prophylactic (non-weight-adjusted) and therapeutic (weight-adjusted) doses, respectively.
LMWHs are predominately eliminated by the renal system after first-order kinetics. There are reported differences between LMWHs for drug clearance (average apparent clearance for enoxaparin, dalteparin, and nadropin are 15, 33, and 21 ml min -1 , respectively). 52, 53 The assessment of anti-Xa levels to determine bleeding risk in patients receiving LMWHs has been earlier called into question. Excessively high anti-Xa levels have been reported after interruption of therapeutic LMWH therapy for >12 h 54 and have also been associated with an increased risk of bleeding. 55 Ellison et al. compared changes in hemostatic markers (anti-Xa, plasma TFPI, plasma thrombin-antithrombin complexes) in women receiving dalteparin, enoxaparin, or tinzaparin for thromboprophylaxis post-cesarean delivery. 56 Anti-Xa levels were significantly higher in groups receiving enoxaparin and dalteparin than the tinzaparin group. Plasma thrombin-antithrombin levels were significantly lower in patients receiving dalteparin and tinzaparin compared with enoxaparin, respectively. No differences in TFPI levels were observed between groups. Future research is needed to better assess the effects of LMWHs on the kinetics of thrombin generation and hemostasis, as there is still uncertainty about the association of these markers with bleeding risk. It is also uncertain how specific changes in hemostasis affect the risk profile associated with spinal hematoma after neuraxial anesthesia.
Fondaparinux
Fondaparinux is a synthetic pentasaccharide, which selectively inhibits factor Xa. Fondaparinux binds with high affinity to antithrombin, leading to a 300-fold increase in factor Xa inhibition. 57 Fondaparinux therapy may be indicated in cases of heparin-induced thrombocytopenia or severe cutaneous allergic reactions to heparin. No studies investigating fondaparinux PK-PD exist in the pregnant population, but there is data in healthy nonpregnant volunteers. 58 After s.c. administration, the bioavailability of fondaparinux approaches 100%. C max levels are achieved at 2 h after s.c. injection, with significant levels (C max /2) within 25 min of administration. Peak plasma levels and the area under the curve of fondaparinux are linearly related to dose. Fondaparinux is primarily eliminated in a dose-independent manner through the kidneys and its elimination half-life is 17 h. There are a few reports of prophylactic fondaparinux administration in pregnant patients; however, these reports lacked details about obstetric anesthetic management. 59, 60 No evidence of placental transfer of fondaparinux was reported in an ex vivo study of high therapeutic doses of fondaparinux. 61 However, Dempfle 62 reported measurable anti-Xa levels in umbilical cord blood, suggesting some placental transfer in vivo. Current recommendations for neuraxial anesthesia in the setting of patients receiving fondaparinux are outlined in Table 1 .
Aspirin Low-dose aspirin irreversibly inhibits platelet function by inhibition of platelet cyclooxygenase-1, which reduces production of thromboxane A2 (vasoconstrictor and platelet aggregator). Although the half-life of aspirin is only 15 to 20 min, its duration of action is 7 to 10 days, consistent with the normal lifespan of platelets. 63, 64 An earlier study of examining the PK of aspirin (75 mg) in pregnant patients reported slower uptake and a lower peak level than in non-pregnant controls. 65 No significant differences in PK were observed between patients at 27 and 29 weeks compared with patients at 36 and 38 weeks. Adequate in vivo hemostasis as measured by thromboelastography has been reported in pregnant patients after aspirin ingestion (600 mg). 66 Kinouchi et al. 67 found that ADP-induced platelet aggregation was decreased in pregnant patients receiving antiplatelet therapy (aspirin 40 mg per day þ dipyridamole 150 mg per day), but remained within a normal range; prothrombin time and APTT values were also not prolonged.
No special precautions are required for patients receiving aspirin alone (75 to 300 mg daily) before neuraxial anesthesia (Table 1) .
Thienopyridines (clopidogrel and ticlopidine)
The risk of acute myocardial infarction is increased during pregnancy, with an estimated incidence of 6 per 100 000 deliveries. 68 Thienopyridines are indicated to prevent coronary stent thrombosis after percutaneous coronary intervention, and act by irreversibly binding to P2Y12 receptors, which reduces ADP-induced activation of glycoprotein IIb/IIIa complexes. The drugs also bind thrombin receptor agonist peptide-induced fibrinogen and P-selectin on platelet membranes. In vivo hepatic transformation to active metabolites for each drug is the most likely mechanism for the antiplatelet effects. The antiplatelet effect of thienopyridines affects between 60 and 70% of ADP receptors. Clopidogrel has a more favorable side-effect profile than ticlodipine. Ticlodipine has been associated with aplastic anemia, thrombocytopenia, and thrombotic thrombocytopenic purpura.
Current recommendations for non-pregnant patients requiring neuraxial anesthesia who are receiving clopidogrel or ticlopidine are outlined in Table 1 . Combination therapy (aspirin þ clopidogrel or ticlodipine) has an additive effect on platelet inhibition, 69 and there are currently no recommended time interval recommendations before and after neuraxial anesthesia with this combination therapy. We are unaware of any studies that have investigated the PK-PD of clopidogrel or ticlopidine in pregnant patients.
In the non-obstetric population, maximal inhibition of ADP-induced platelet aggregation occurs within 5 h of clopidogrel administration (200 to 600 mg). 70 Platelet aggregation inhibition reaches steady state with clopidogrel or ticlopidine after 6 days of daily dosing (52 and 43% inhibition by 75 mg clopidogrel and 250 mg b.i.d. ticlopidine daily, respectively). 71 Normal platelet function is achieved in 7 days after termination of clopidogrel therapy; however, these assessments are based on recovery of bleeding times. 71 Clopidogrel is rapidly absorbed from the gastrointestinal tract after oral ingestion. A dose-proportional increase in C max occurs with doses between 50 and 150 mg clopridogrel. 72 Clopidogrel is extensively metabolized by the cytochrome P450 system and is six times more potent than ticlodipine. Inactive metabolites of clopidogrel are renally excreted at a constant rate accounting for its linear PK profile. The T max of clopidogrel is 0.8 to 1.0 h, and the terminal half-life of the main circulating metabolite is 7.5 h. 73 The oral bioavailability of ticlopidine is up to 90%, and the drug shows platelet inhibition as soon as 1 h after oral administration. 74 The maximal inhibition of platelet function occurs after 3 to 5 days of administration. 75 The apparent elimination half-life is 24 to 36 h after a single oral dose; 76 however, recovery of platelet function after discontinuation of ticlodipine occurs slowly over 3 to 8 days. 74, 75 Ticlodipine has non-linear PKs, and its clearance decreases with repeat dosing. 77 
Warfarin
The anticoagulant effect of warfarin occurs as a result of interference of g-carboxylation of glutamate residues (G1a) on the N-terminal regions of vitamin K-dependent proteins (factors II, VII, IX, and X). The dose response can differ between subjects, 78 and genetic and environmental factors (drugs, diet, and disease states) can also affect PK-PD characteristics of warfarin. 79 The anticoagulant effects of warfarin are most commonly monitored using the prothrombin time. At the initiation of warfarin therapy, prothrombin time is predominately affected by depression of factor VII, which has the shortest half-life (5 h) of the vitamin K-dependent clotting factors. 80 The antithrombotic effect of warfarin occurs after reduction of prothrombin, which has a much longer half-life (60 to 72 h).
An earlier study comparing warfarin dosage in postpartum patients with non-pregnant patients found that postpartum patients required significantly longer time and higher doses of warfarin to attain therapeutic levels of anticoagulation. 81 Higher factor II, VII, and X levels in the postpartum period probably substantiated higher therapeutic warfarin dosing in this patient subpopulation. Guidelines for performing neuraxial anesthesia in patients on warfarin therapy are described in Table 1 .
Peripartum management
The management of anticoagulated parturients during the peripartum and postpartum periods may vary between institutions and among individual physicians. In our experience, UFH and LMWHs are the most common anticoagulants encountered in obstetric patients during the peripartum and postpartum periods. Suggested algorithms for managing pregnant patients receiving prophylactic UFH and LMWH during labor and for cesarean delivery are shown in Figures 1-4 . Suggested algorithms for patients receiving therapeutic UFH and LMWH are outlined in Figures 5 and 6 . We have based these algorithms on published guidelines from American Society of Regional Anesthesia and European anesthesia societies, as well as on our clinical experience. However, we acknowledge that optimal times for resuming anticoagulation (UFH and LMWH) after delivery may vary between 12 and 24 h after delivery. 13, 82, 83 These algorithms should only be used as a general guide and management of these high-risk patients must be individualized. If patients require epidural analgesia after cesarean delivery and anticoagulation is restarted, then anesthesia consultation and review is necessary for deciding the optimal timing of epidural catheter removal (according to national anesthesia society guidelines).
Management of anticoagulant-related bleeding
The management of an anticoagulated parturient with severe obstetric hemorrhage can be challenging. The rate and magnitude of blood loss requires careful assessment, and therapeutic measures should be instituted appropriate to the severity of bleeding. Patients require continuous clinical assessment and should receive early intravenous fluid resuscitation to maintain hemodynamic stability. Anticoagulant therapy should be discontinued, and identification of surgical causes of bleeding is necessary. Early laboratory assessment of the coagulation system is warranted (including prothrombin time, APTT, fibrinogen, platelet count) as well as anticoagulant drug levels (as appropriate). Transfusion of fresh frozen plasma, cryoprecipitate, and factor concentrates should be Therapeutic strategies and pharmacological agents for anticoagulant reversal have been described earlier. [84] [85] [86] [87] Protamine sulfate can fully reverse the effects of UFH; however, there is incomplete reversal for LMWH. 88 Recombinant factor VIIa is efficacious in reversing the anticoagulant effect of LMWH in vitro, 89 and there are anecdotal reports of successful acute reversal of LMWH with recombinant factor VIIa. 90 Although warfarin is not routinely used for anticoagulation during the peripartum period, therapeutic measures for the acute reversal of warfarin have been described earlier 85 (including fresh frozen plasma, prothrombin complex concentrates, or recombinant factor VIIa). We recommend close consultation with hematology specialists for advice on managing the acute reversal of anticoagulation in the peripartum setting.
Conclusion
Recommendations from national anesthetic societies should be used in all patients receiving anticoagulation before or after neuraxial anesthesia. However, there is limited understanding of the dynamic changes in PK-PD of individual anticoagulant and antithrombotic drugs that occur with advancing gestation, and how these potential changes affect the risk profile of pregnant patients undergoing neuraxial anesthesia or surgical intervention. Future studies are needed to assess management practices of highrisk anticoagulated patients during the peripartum period to minimize anesthetic (spinal hematoma after neuraxial anesthesia) and surgical (postpartum hemorrhage) adverse outcomes. In addition, the development of novel anticoagulants and expanding clinical applications for pregnant patients will pose unique future challenges to obstetric and anesthesia care providers. 11 We recommend that the decision to proceed with neuraxial anesthesia in parturients receiving anticoagulants or antithrombotic drugs should be based on careful, individual risk-benefit assessment before delivery.
